#Reallife #data #Beyfortus #published #Lancet
Sanofi
SAN – FR0000120578
Listing on 04/30/2024 at 00:00
€ 93,080 0,00%
Beyfortus reduced the risk of hospitalizations due to respiratory syncytial virus (RSV) by 82% (95% CI: 65.6 to 90.2) in…
Photo credit Sanofi Corporate
Par Hector Chaunu
Published on 05/02/2024 at 7:55 a.m.
Beyfortus reduced the risk of hospitalizations due to respiratory syncytial virus (RSV) by 82% (95% CI: 65.6 to 90.2) in infants under six months of age, compared to infants without not been immunized against RSV, according to interim results of an ongoing study published in The Lancet.
These results, which correspond to the first season of RSV circulation since the introduction of Beyfortus, are part of the three-year NIRSE-GAL study carried out in Galicia (Spain), as part of a collaboration with the General Directorate of Public Health of the Regional Administration of the Autonomous Community of Galicia (Xunta de Galicia) and Sanofi.
These results echo real-life data collected as part of several large-scale immunization programs conducted among infant populations in the United States, Spain and France during the 2023-2024 viral season .
They also support the high and consistent effectiveness observed in the pivotal clinical trials devoted to Beyfortus. A favorable safety profile was observed following administration of Beyfortus, consistent with results obtained in clinical trials1-10.
Federico Martinon Torres, Head of Pediatrics, University Hospital of Santiago, Spain, and principal investigator of the NIRSE-GAL study, highlights: “The study carried out in Galicia provides the first real-life data in the general population of the preventive impact of nirsevimab on RSV infections in infants and show that this treatment makes it possible to reduce the number of hospitalizations due to the virus by almost 90%, compared to several previous seasons of RSV circulation. credit for the exemplary pragmatic collaboration established between researchers, the pharmaceutical sector, health professionals and decision-makers with a view to the deployment of a carefully orchestrated preventive immunization campaign and the remarkable support it received from Galician parents .”
Thomas Triomphe, Executive Vice President, Vaccines, Sanofi comments: “The scale and speed of the impact of Beyfortus observed in the wake of its introduction on the market, illustrate the power of strategies to immunize all infants against RSV In Galicia, we observed the effectiveness of this type of strategy which resulted in an 82% reduction in hospitalizations due to RSV after the launch of Beyfortus, and in the immunization of more than 90% of patients. eligible infants. The growing body of evidence from these programs supports decision-makers, health professionals and parents who share with us the ambition to protect infants against infections due to this virus.
